Review Article

You have free access to this content

Common infections in diabetes: pathogenesis, management and relationship to glycaemic control

  1. Anton Y. Peleg1,†,
  2. Thilak Weerarathna2,
  3. James S. McCarthy1,3,
  4. Timothy M. E. Davis2,*

Article first published online: 8 SEP 2006

DOI: 10.1002/dmrr.682

Issue

Diabetes/Metabolism Research and Reviews

Diabetes/Metabolism Research and Reviews

Volume 23, Issue 1, pages 3–13, January 2007

Additional Information

How to Cite

Peleg, A. Y., Weerarathna, T., McCarthy, J. S. and Davis, T. M. E. (2007), Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab. Res. Rev., 23: 3–13. doi: 10.1002/dmrr.682

Author Information

  1. 1

    Department of Infectious Diseases, Royal Brisbane and Women's Hospital, Herston, Brisbane, Australia

  2. 2

    University of Western Australia, School of Medicine and Pharmacology, Fremantle Hospital, Fremantle, Australia

  3. 3

    The Queensland Institute of Medical Research and Australian Centre for International and Tropical Health and Nutrition, The University of Queensland, Brisbane, Australia

  1. †

    Division of Infection Diseases, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA.

*School of Medicine and Pharmacology, Fremantle Hospital, PO Box 480, Fremantle, Western Australia 6959, Australia.

Publication History

  1. Issue published online: 28 DEC 2006
  2. Article first published online: 8 SEP 2006
  3. Manuscript Accepted: 1 AUG 2006
  4. Manuscript Received: 8 JUN 2006

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (152K)

References

  • 1
    Bell JI, Hockaday TDR. Diabetes mellitus. In Oxford Textbook of Medicine (3rd edn), WetherallDJ, LedinghamJGG, WarrellDA (eds). Oxford University Press: Oxford, 1996; 1448–1504.
  • 2
    Shah BR, Hux JE. Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care 2003; 26: 510–513.
  • 3
    UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853.
  • 4
    The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986.
  • 5
    Bagdade JD, Root RK, Bulger RJ. Impaired leukocyte function in patients with poorly controlled diabetes. Diabetes 1974; 23: 9–15.
  • 6
    Nolan CM, Beaty HN, Bagdade JD. Further characterization of the impaired bactericidal function of granulocytes in patients with poorly controlled diabetes. Diabetes 1978; 27: 889–894.
  • 7
    Delamaire M, Maugendre D, Moreno M, Le Goff MC, Allannic H, Genetet B. Impaired leucocyte functions in diabetic patients. Diabet Med 1997; 14: 29–34.
    Direct Link:
  • 8
    Collison KS, Parhar RS, Saleh SS, et al. RAGE-mediated neutrophil dysfunction is evoked by advanced glycation end products (AGEs). J Leukoc Biol 2002; 71: 433–444.
  • 9
    Mowat A, Baum J. Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. N Engl J Med 1971; 284: 621–627.
  • 10
    Hill HR, Sauls HS, Dettloff JL, Quie PG. Impaired leukotactic responsiveness in patients with juvenile diabetes mellitus. Clin Immunol Immunopathol 1974; 2: 395–403.
  • 11
    Molenaar DM, Palumbo PJ, Wilson WR, Ritts RE Jr. Leukocyte chemotaxis in diabetic patients and their nondiabetic first-degree relatives. Diabetes 1976; 25: 880–883.
  • 12
    Miller ME, Baker L. Leukocyte functions in juvenile diabetes mellitus: humoral and cellular aspects. J Pediatr 1972; 81: 979–982.
  • 13
    Hill HR, Augustine NH, Rallison ML, Santos JI. Defective monocyte chemotactic responses in diabetes mellitus. J Clin Immunol 1983; 3: 70–77.
  • 14
    Walrand S, Guillet C, Boirie Y, Vasson MP. In vivo evidences that insulin regulates human polymorphonuclear neutrophil functions. J Leukoc Biol 2004; 76: 1104–1110.
  • 15
    Marhoffer W, Stein M, Maeser E, Federlin K. Impairment of polymorphonuclear leukocyte function and metabolic control of diabetes. Diabetes Care 1992; 15: 256–260.
  • 16
    Wilson RM, Reeves WG. Neutrophil phagocytosis and killing in insulin-dependent diabetes. Clin Exp Immunol 1986; 63: 478–484.
  • 17
    Dziatkowiak H, Kowalska M, Denys A. Phagocytic and bactericidal activity of granulocytes in diabetic children. Diabetes 1982; 31: 1041–1043.
  • 18
    Tater D, Tepaut B, Bercovici JP, Youinou P. Polymorphonuclear cell derangements in type I diabetes. Horm Metab Res 1987; 19: 642–647.
  • 19
    Gin H, Brottier E, Aubertin J. Influence of glycaemic normalisation by an artificial pancreas on phagocytic and bactericidal functions of granulocytes in insulin dependent diabetic patients. J Clin Pathol 1984; 37: 1029–1031.
  • 20
    Repine JE, Clawson CC, Goetz FC. Bactericidal function of neutrophils from patients with acute bacterial infections and from diabetics. J Infect Dis 1980; 142: 869–875.
  • 21
    Rayfield EJ, Ault MJ, Keusch GT, Brothers MJ, Nechemias C, Smith H. Infection and diabetes: the case for glucose control. Am J Med 1982; 72: 439–450.
  • 22
    Mazade MA, Edwards MS. Impairment of type III group B Streptococcus-stimulated superoxide production and opsonophagocytosis by neutrophils in diabetes. Mol Genet Metab 2001; 73: 259–267.
  • 23
    Suzuki K, Kawamura T, Sakakibara F, et al. Effect of aldose reductase inhibitors on glucose-induced changes in sorbitol and myo-inositol metabolism in human neutrophils. Diabet Med 1999; 16: 67–73.
    Direct Link:
  • 24
    Kawamura T, Suzuki K, Matsumae H, Sano T, Sakamoto N, Hotta N. Effects of glucose and SNK-860, an aldose reductase inhibitor, on the polyol pathway and chemiluminescence response of human neutrophils in vitro. Diabet Med 1995; 12: 392–396.
    Direct Link:
  • 25
    Sato N, Kashima K, Uehara Y, Ohtani K, Shimizu H, Mori M. Epalrestat, an aldose reductase inhibitor, improves an impaired generation of oxygen-derived free radicals by neutrophils from poorly controlled NIDDM patients. Diabetes Care 1997; 20: 995–998.
  • 26
    Gough A, Clapperton M, Rolando N, Foster AV, Philpott-Howard J, Edmonds ME. Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. Lancet 1997; 350: 855–859.
  • 27
    Sato N, Kashima K, Tanaka Y, Shimizu H, Mori M. Effect of granulocyte-colony stimulating factor on generation of oxygen-derived free radicals and myeloperoxidase activity in neutrophils from poorly controlled NIDDM patients. Diabetes 1997; 46: 133–137.
  • 28
    Yonem A, Cakir B, Guler S, Azal OO, Corakci A. Effects of granulocyte-colony stimulating factor in the treatment of diabetic foot infection. Diabetes Obes Metab 2001; 3: 332–337.
    Direct Link:
  • 29
    MacCuish AC, Urbaniak SJ, Campbell CJ, Duncan LJ, Irvine WJ. Phytohemagglutinin transformation and circulating lymphocyte subpopulations in insulin-dependent diabetic patients. Diabetes 1974; 23: 708–712.
  • 30
    Casey JI, Heeter BJ, Klyshevich KA. Impaired response of lymphocytes of diabetic subjects to antigen of Staphylococcus aureus. J Infect Dis 1977; 136: 495–501.
  • 31
    Eibl N, Spatz M, Fischer GF, et al. Impaired primary immune response in type-1 diabetes: results from a controlled vaccination study. Clin Immunol 2002; 103: 249–259.
  • 32
    Pozzilli P, Pagani S, Arduini P, et al. In vivo determination of cell mediated immune response in diabetic patients using a multiple intradermal antigen dispenser. Diabetes Res 1987; 6: 5–8.
  • 33
    Spatz M, Eibl N, Hink S, et al. Impaired primary immune response in type-1 diabetes. Functional impairment at the level of APCs and T-cells. Cell Immunol 2003; 221: 15–26.
  • 34
    Lapolla A, Tonani R, Fedele D, et al. Non-enzymatic glycation of IgG: an in vivo study. Horm Metab Res 2002; 34: 260–264.
  • 35
    Diepersloot RJ, Bouter KP, van Beek R, Lucas CJ, Masurel N, Erkelens DW. Cytotoxic T-cell response to influenza a subunit vaccine in patients with type 1 diabetes mellitus. Neth J Med 1989; 35: 68–75.
  • 36
    Pozzilli P, Gale EA, Visalli N, et al. The immune response to influenza vaccination in diabetic patients. Diabetologia 1986; 29: 850–854.
  • 37
    Feery BJ, Hartman LJ, Hampson AW, Proietto J. Influenza immunization in adults with diabetes mellitus. Diabetes Care 1983; 6: 475–478.
  • 38
    Friedman EA, Beyer MM, Hirsch SR, Schiffman G. Intact antibody response to pneumococcal capsular polysaccharides in uremia and diabetes. JAMA 1980; 244: 2310–2311.
  • 39
    Beam TR Jr, Crigler ED, Goldman JK, Schiffman G. Antibody response to polyvalent pneumococcal polysaccharide vaccine in diabetics. JAMA 1980; 244: 2621–2624.
  • 40
    el-Madhun AS, Cox RJ, Seime A, Sovik O, Haaheim LR. Systemic and local immune responses after parenteral influenza vaccination in juvenile diabetic patients and healthy controls: results from a pilot study. Vaccine 1998; 16: 156–160.
  • 41
    Lederman MM, Schiffman G, Rodman HM. Pneumococcal immunization in adult diabetics. Diabetes 1981; 30: 119–121.
  • 42
    Douvin C, Simon D, Charles MA, et al. Hepatitis B vaccination in diabetic patients. Randomized trial comparing recombinant vaccines containing and not containing pre-S2 antigen. Diabetes Care 1997; 20: 148–151.
  • 43
    Marseglia GL, Scaramuzza A, d'Annunzio G, Comolli G, Gatti M, Lorini R. Successful immune response to a recombinant hepatitis B vaccine in young patients with insulin-dependent diabetes mellitus. Diabet Med 1996; 13: 630–633.
    Direct Link:
  • 44
    Marseglia G, Alibrandi A, d'Annunzio G, et al. Long term persistence of anti-HBs protective levels in young patients with type 1 diabetes after recombinant hepatitis B vaccine. Vaccine 2000; 19: 680–683.
  • 45
    Diepersloot RJ, Bouter KP, Beyer WE, Hoekstra JB, Masurel N. Humoral immune response and delayed type hypersensitivity to influenza vaccine in patients with diabetes mellitus. Diabetologia 1987; 30: 397–401.
  • 46
    Bridges CB, Harper SA, Fukuda K, Uyeki TM, Cox NJ, Singleton JA. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2003; 52: 1–34.
  • 47
    Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46: 1–24.
  • 48
    Smith SA, Poland GA. Influenza and pneumococcal immunization in diabetes. Diabetes Care 2004; 27(Suppl. 1): S111–S113.
  • 49
    Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005; 54(RR-8): 1–40.
  • 50
    Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 2005; Nov 15; 41(10): 1373–1406.
  • 51
    Lipsky BA, Berendt AR, Deery HG, et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2004; 39(7): 885–910.
  • 52
    Mandell LA, Bartlett JG, Dowell SF, File TM Jr, Musher DM, Whitney C. Infectious diseases society of America. Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults. Clin Infect Dis 2003; Dec 1; 37(11): 1405–1433.
  • 53
    Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM. Infectious diseases society of America; American society of nephrology; American geriatric society. Infectious diseases society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis 2005; 40(5): 643–654.
  • 54
    Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis 1999; 29(4): 745–758.
  • 55
    Romano G, Moretti G, Benedetto A, et al. Skin lesions in diabetes mellitus: prevalence and clinical correlations. Diabetes Res Clin Pract 1998; 39: 101–106.
  • 56
    Currie CJ, Morgan CL, Peters JR. The epidemiology of inpatient care for peripheral vascular disease, infection, neuropathy and ulceration in diabetes. Diabetes Care 1998; 21: 42–47.
  • 57
    Muller LM, Gorter KJ, Hak E, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 2005; 41: 281–288.
  • 58
    Ahluwalia A, Sood A, Sood A, Lakshmy R, Kapil A, Pandey RM. Nasal colonization with Staphylococcus aureus in patients with diabetes mellitus. Diabet Med 2000; 17: 487–488.
  • 59
    Smith JA, O'Connor JJ, Wills AT. Nasal carriage of Staphylococcus aureus in diabetes mellitus. Lancet 1996; ii: 8776–8777.
  • 60
    Leibovici L, Yehezkelli Y, Porter A, Regev A, Krauze I, Harell D. Influence of diabetes mellitus and glycaemic control on the characteristics and outcome of common infections. Diabet Med 1996; 13: 457–463.
    Direct Link:
  • 61
    Chandler PT, Chandler SD. Pathogenic carrier rate in diabetes mellitus. Am J Med Sci 1977; 273: 259–265.
  • 62
    Lipsky BA, Pecoraro RE, Chen MS, Koepsell TD. Factors affecting staphylococcal colonization among NIDDM patients. Diabetes Care 1978; 10: 483–486.
  • 63
    Tuazon CU, Perez A, Kishaba T, Sheagren JN. Staphylococcus aureus among insulin-injecting diabetic patients. JAMA 1975; 231: 1272.
  • 64
    Breen JD, Karchmer AW. Staphylococcus aureus infections in diabetic patients. Infect Dis Clin North Am 1995; 9: 11–24.
  • 65
    Harris RA, Hardman DTA, Brown AR. Cellulitis and the occult diabetic. Aust N Z J Surg 1996; 66: 175–177.
    Direct Link:
  • 66
    Gupta AK, Konnikov N, MacDonald P, et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre study. Br J Dermatol 1998; 138: 665–671.
    Direct Link:
  • 67
    Cribier BJ, Bakshi R. Terbinafine in the treatment of onychomycosis: a review of its efficacy in high-risk populations and in patients with nondermatophyte infections. Br J Dermatol 2004; 150: 414–420.
    Direct Link:
  • 68
    Soysa NS, Samaranayake LP, Ellepola ANB. Diabetes mellitus as a contributory factor in oral candidosis. Diabet Med 2006; 23: 455–459.
    Direct Link:
  • 69
    Hosteter MK. Effects of hyperglycaemia on C3 and Candida albicans. Diabetes 1990; 39: 271–275.
  • 70
    Belazi M, Velegraki A, Fleva A, et al. Candidal overgrowth in diabetic patients: potential predisposing factors. Mycoses 2005; 48: 192–196.
    Direct Link:
  • 71
    Lipsky BA, Berendt AR, Embil J, De Lalla F. Diagnosing and treating diabetic foot infections. Diabetes Metab Res Rev 2004; 20(Suppl. 1): S56–S64.
    Direct Link:
  • 72
    Pittet D, Wyssa B, Herter-Clavel C, Kursteiner K, Vaucher J, Lew PD. Outcome of diabetic foot infections treated conservatively: a retrospective cohort study with long-term follow-up. Arch Intern Med 1999; 159: 851–856.
  • 73
    Lipsky BA. Medical treatment of diabetic foot infections. Clin Infect Dis 2004; 39(Suppl. 2): S104–S114.
  • 74
    Slater RA, Lazarovitch T, Boldur I, et al. Swab cultures accurately identify bacterial pathogens in diabetic foot wounds not involving bone. Diabet Med 2004; 21: 705–709.
    Direct Link:
  • 75
    Edmonds M, Foster A. The use of antibiotics in the diabetic foot. Am J Surg 2004; 187(5A): 25S–28S.
  • 76
    van Baal JG. Surgical treatment of the infected diabetic foot. Clin Infect Dis 2004; 39(Suppl. 2): S123–S128.
  • 77
    Reiber GE, Raugi GJ. Preventing foot ulcers and amputations in diabetes. Lancet 2005; 366: 1676–1677.
  • 78
    Cavanagh PR, Lipsky BA, Bradbury AW, Botek G. Treatment for diabetic foot ulcers. Lancet 2005; 366: 1725–1735.
  • 79
    Fleming DM, Crombie DL, Cross KW. Disease concurrence in diabetes mellitus: a study of concurrent morbidity over 12 months using diabetes mellitus as an example. J Epidemiol Commun Hlth 1991; 45: 73–77.
  • 80
    Woodhead MA, Macfarlane JT, McCracken JS, Rose DS, Finch RG. Prospective study of aetiology and outcome of pneumonia in the community. Lancet 1987; 27: 671–674.
  • 81
    Mackowiak PA, Martin RM, Jones SR, Smith JW. Pharyngeal colonization by Gram-negative bacilli in aspiration-prone persons. Arch Int Med 1978; 138: 1224–1227.
  • 82
    Fine MJ, Smith MA, Carson CA, et al. Prognosis and outcome of patients with community-acquired pneumonia. A meta-analysis. JAMA 1995; 274: 134–141.
  • 83
    Winterbauer RH, Bedon GA, Ball WA. Recurrent pneumonia. Predesposing illness and clinical patterns in 158 patients. Ann Intern Med 1969; 70: 689–692.
  • 84
    Marrie TJ. Bacteraemic pneumococcal disease. J Infect 1992; 24: 245–255.
  • 85
    Watanakunakorn C, Bailey TA. Adult bacteremic pneumococcal pneumonia in a community teaching hospital, 1992–1996. Arch Intern Med 1997; 157: 1965–1971.
  • 86
    Thomsen RW, Hundborg HH, Lervang HH, Johnsen SP, Sorensen HT, Schonheyder HC. Diabetes and outcome of community-acquired pneumococcal bacteremia: a 10-year population-based cohort study. Diabetes Care 2004; 27: 70–76.
  • 87
    Barker WH, Mullooly JP. Pneumonia and influenza deaths during epidemics. Arch Intern Med 1982; 142: 85–89.
  • 88
    Burrow GN, Hazlett BE, Phillips MJ. A case of diabetes mellitus. N Engl J Med 1982; 11: 340–343.
  • 89
    Goslings WRO, Mulder J, Djajadiningrat J, Masurel M. Staphylococcal pneumonia in influenza. Lancet 1959; ii: 428–430.
  • 90
    Luntz GRWN. Management of the tuberculous diabetic. Follow-up of 84 cases of for one year. BMJ 1957; i: 1076–1080.
  • 91
    Yamagashi F, Suzuki K, Sasaki Y, Saitoh M, Izumizaki M, Koizumi K. Prevalence of coexisting diabetes mellitus among patients with active tuberculosis. Kekkaku 1996; 10: 27–31.
  • 92
    Javed F, Shera AS, Memon R, Ansari G. Glucose intolerance in pulmonary tuberculosis. J Pak Med Assoc 1995; 45: 237–238.
  • 93
    Patel MS. Bacterial infections among patients with pulmonary tuberculosis in Papua New Guinea. Med J Aust 1989; 50: 25–28.
  • 94
    Kozeil H, Kozeil MJ. Pulmonary complications of diabetes mellitus. Infect Dis Clin North Am 1995; 9: 65–95.
  • 95
    Kameda K, Kawabata S, Masuda N. Follow-up study of chort course chemotherapy of pulmonary tuberculosis complicated with diabetes mellitus. Kekkaku 1990; 65: 791–803.
  • 96
    Cheren'ko SA. Intermittent polychemotherapy of patients with chronic destructive pulmonary tuberculosis with associated diabetes mellitus. Probl Tuberk 1989; 8: 48–50.
  • 97
    Patterson JE, Andriole VT. Bacterial urinary tract infections in diabetes mellitus. Infect Dis Clin North Am 1997; 11: 735–750.
  • 98
    Zhanel GG, Harding GKM, Nicolle LE. Asymptomatic bacteriuria in patients with diabetes mellitus. Rev Infect Dis 1991; 13: 150–154.
  • 99
    Stapleton A. Urinary tract infections in patients with diabetes. Am J Med 2002; 113(Suppl. 1A): 80S–84S.
  • 100
    Geerlings SE, Stolk RP, Camps MJ, et al. Consequences of asymptomatic bacteriuria in women with diabetes mellitus. Arch Intern Med 2001; 161: 1421–1427.
  • 101
    Harding GK, Zhanel GG, Nicolle LE, Cheang M. Manitoba Diabetes Urinary Tract Infection Study Group. Antimicrobial treatment in diabetic women with asymptomatic bacteriuria. N Engl J Med 2002; 347: 1576–1583.
  • 102
    Karunajeewa H, McGechie D, Stuccio G, Stingemore N, Davis WA, Davis TME. Asymptomatic bacteriuria as a predictor of subsequent hospitalisation with urinary tract infection in diabetic adults: The Fremantle Diabetes Study. Diabetologia 2005; 48: 1288–1291.
  • 103
    Bonadio M, Boldrini E, Forotti G, et al. Asymptomatic bacteriuria in women with diabetes: influence of metabolic control. Clin Infect Dis 2004; 38: e41–e45.
  • 104
    Geerlings S, Stolk R, Camps M, et al. Hoepelman AI: asymptomatic bacteriuria may be considered a complication in women with diabetes. Diabetes mellitus women asymptomatic bacteriuria utrecht study group. Diabetes Care 2000; 23: 744–749.
  • 105
    Zahnel GG, Nicolle LE, Harding GKM. Prevalence of asymptomatic bacteriuria and associated host factors in women with diabetes mellitus. Clin Infect Dis 1995; 21: 316–322.
  • 106
    Forland M, Thomas V, Shelokov A. Urinary tract infections with patients with diabetes mellitus. JAMA 1977; 238: 1924–1926.
  • 107
    Zahnel GG, Harding GK, Guay DR. Asymptomatic bacteriuria. Which patients should be treated? Arch Intern Med 1990; 150: 1389–1396.
  • 108
    Ooi ST, Frazee LA, Gardner WG. Management of asymptomatic bacteriuria in patients with diabetes mellitus. Ann Pharmacother 2004; 38: 490–493.
  • 109
    Nicolle LE, Frieson D, Harding GKM. Hospitalization for acute pyelonephritis in Manitoba, Canada, during the period from 1989 to 1992: impact of diabetes, pregnancy and Aboriginal origin. Clin Infect Dis 1996; 22: 1051–1056.
  • 110
    Evanoff GV, Thompson GS, Foley R, Weinman EJ. Spectrum of gas within the kidney. Am J Med 1987; 83: 149–152.
  • 111
    Horcajada JP, Moreno I, Velasco M, et al. Community-acquired febrile urinary tract infection in diabetics could deserve a different management: a case-control study. J Intern Med 2003; 254: 280–286.
    Direct Link:
  • 112
    Taylor GW, Manz MC, Borgnakke WS. Diabetes, periodontal diseases, dental caries, and tooth loss: a review of the literature. Compend Contin Educ Dent 2004; 25: 179–190.
  • 113
    Finney LS, Finney MO, Gonzalez-Campoy JM. What the mouth has to say about diabetes. Careful examinations can avert serious complications. Postgrad Med 1997; 102: 117–126.
  • 114
    Loe H. Periodontal disease. The sixth complication of diabetes mellitus. Diabetes Care 1993; 16: 329–334.
  • 115
    Novaes AB Jr, Gonzalez Gutierrez F, Grisi MF, Novaes AB. Periodontal disease progression in type II non-insulin-dependent diabetes melltius patients (NIDDM). Part II–microbiological analysis using the BANA test. Braz Dent J 1997; 8: 27–33.
  • 116
    Grossi SG, Skrepcinski FB, DeCaro T, et al. Treatment of periodontal disease in diabetics reduced glycated hemoglobin. J Periodontol 1997; 68: 713–719.
  • 117
    Tervonen T, Karjalainen K. Periodontal disease related to diabetic status. A pilot study of the response to peridontal therapy in type 1 diabetes. J Clin Periodontol 1997; 24: 505–510.
    Direct Link:
  • 118
    Seppala B, Sorsa T, Ainamo J. Morphometric analysis of cellular and vascular changes in gingival connective tissue in long-term insulin-dependent diabetes. J Periodontol 1997; 68: 1237–1245.
  • 119
    Grossi SG, Genco RJ. Periodontal disease and diabetes mellitus: a two-way relationship. Ann Periodontol 1998; 3: 51–61.
  • 120
    Martorelli de Lima AF, Cury CC, Palioto DB, Duro AM, da Silva RC, Wolff LF. Therapy with adjunctive doxycycline local delivery in patients with type 1 diabetes mellitus and periodontitis. J Clin Periodontol 2004; 31: 648–653.
    Direct Link:
  • 121
    Adverse events and their association with treatment regimens in the Diabetes Control and Complications Trial. Diabetes Care 1995; 18: 1415–1427.
  • 122
    Davis TME, Weeraratna T, Mason C, Davis WA. Community-acquired infections in diabetic patients and their non-diabetic partners: The Fremantle Diabetes Study. J Diab Compl 2005; 19: 259–263.
  • 123
    Zacharias A, Habib RH. Factors predisposing to median sternotomy complications. Deep vs superficial infection. Chest 1996; 110: 1173–1178.
  • 124
    Vuorisalo S, Haukipuro K, Pokela R, Syrjala H. Risk features for surgical-site infections in coronary artery bypass surgery. Infect Control Hosp Epidemiol 1998; 19: 240–247.
  • 125
    Borger MA, Rao V, Weisel RD, et al. Deep sternal wound infection: risk factors and outcomes. Ann Thorac Surg 1998; 65: 1050–1056.
  • 126
    Latham R, Lancaster AD, Covington JF, Pirolo JS, Thomas CS. The association of diabetes and glucose control with surgical-site infections among cardiothoracic surgery patients. Infect Control Hosp Epidemiol 2001; 22: 607–612.
  • 127
    Trick WE, Scheckler WE, Tokars JI, et al. Modifiable risk factors associated with deep sternal site infection after coronary artery bypass grafting. J Thorac Cardiovasc Surg 2000; 119: 108–114.
  • 128
    Szabo Z, Hakanson E, Svedjeholm R. Early postoperative outcome and medium-term survival in 540 diabetic and 2239 nondiabetic patients undergoing coronary artery bypass grafting. Ann Thorac Surg 2002; 74: 712–719.
  • 129
    Pomposelli JJ, Baxter JK III, Babineau TJ, et al. Early postoperative glucose control predicts nosocomial infection rate in diabetic patients. JPEN J Parenter Enteral Nutr 1998; 22: 77–81.
  • 130
    Russo PL, Spelman DW. A new surgical-site infection risk index using risk factors identified by multivariate analysis for patients undergoing coronary artery bypass graft surgery. Infect Control Hosp Epidemiol 2002; 23: 372–376.
  • 131
    Trick WE, Scheckler WE, Tokars JI, et al. Risk factors for radial artery harvest site infection following coronary artery bypass graft surgery. Clin Infect Dis 2000; 30: 270–275.
  • 132
    Zerr KJ, Furnary AP, Grunkemeier GL, Bookin S, Kanhere V, Starr A. Glucose control lowers the risk of wound infection in diabetics after open heart operations. Ann Thorac Surg 1997; 63: 356–361.
  • 133
    Furnary AP, Zerr KJ, Grunkemeier GL, Starr A. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 1999; 67: 352–360.
  • 134
    Rassias AJ, Marrin CA, Arruda J, Whalen PK, Beach M, Yeager MP. Insulin infusion improves neutrophil function in diabetic cardiac surgery patients. Anesth Analg 1999; 88: 1011–1016.
  • 135
    McMahon MM, Bistrian BR. Host defenses and susceptibility to infection in patients with diabetes mellitus. Infect Dis Clin North Am 1995; 9: 1–9.
  • 136
    van den Berghe G, Wouters P, Verwaest C, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001; 345: 1359–1367.
  • 137
    Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006; 354: 449–461.
View Full Article (HTML) Get PDF (152K)